CelLBxHealth plc
ANPCY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.04 | 0.00 | 0.08 |
| FCF Yield | -10.96% | -7.82% | -9.94% | -11.39% |
| EV / EBITDA | -4.28 | -6.14 | -9.01 | -7.62 |
| Quality | ||||
| ROIC | -32.11% | -32.11% | -14.16% | -14.16% |
| Gross Margin | 58.54% | 58.54% | 63.89% | 63.89% |
| Cash Conversion Ratio | 0.50 | 0.50 | 1.02 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.28% | 12.05% | 22.38% | 21.05% |
| Free Cash Flow Growth | 0.00% | 32.44% | 0.00% | -0.38% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 0.35 | 1.95 | 1.95 |
| Interest Coverage | -175.95 | -175.95 | -18.07 | -18.07 |
| Efficiency | ||||
| Inventory Turnover | 0.10 | 0.10 | 0.21 | 0.21 |
| Cash Conversion Cycle | 37.58 | 37.58 | 418.14 | 31.50 |